|Bid||837.00 x 0|
|Ask||838.50 x 0|
|Day's range||833.00 - 870.50|
|52-week range||8.30 - 940.00|
|Beta (5Y monthly)||1.22|
|PE ratio (TTM)||86.65|
|Forward dividend & yield||0.08 (0.90%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||N/A|
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has launched its Malaysian business with an office in Kuala Lumpur. The new office is part of Clinigen’s strategy to expand its footprint in Southeast Asia, an important market for the Group.
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Services (CS) business has expanded its exclusive ’on-demand’ supply service with Accord Healthcare (‘Accord’) into France. Through this arrangement, Clinigen’s CS customers will continue to access the Accord portfolio – both UK and EU packs of product – for their clinical trials worldwide.